L&C Bio Co., Ltd

KOSDAQ 290650.KQ

L&C Bio Co., Ltd Cash and Short-Term Investments for the year ending December 31, 2023: USD 45.46 M

L&C Bio Co., Ltd Cash and Short-Term Investments is USD 45.46 M for the year ending December 31, 2023, a 367.21% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

L&C Bio Co., Ltd Cash and Short-Term Investments for the year ending December 31, 2022 was USD 9.73 M, a -40.75% change year over year.
L&C Bio Co., Ltd Cash and Short-Term Investments for the year ending December 31, 2021 was USD 16.42 M, a -34.58% change year over year.
L&C Bio Co., Ltd Cash and Short-Term Investments for the year ending December 31, 2020 was USD 25.10 M, a 0.72% change year over year.
L&C Bio Co., Ltd Cash and Short-Term Investments for the year ending December 31, 2019 was USD 24.92 M, a -23.80% change year over year.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

KOSDAQ: 290650.KQ

L&C Bio Co., Ltd

CEO	Mr. Chul Lee Whan
IPO Date	Nov. 1, 2018
Location	South Korea
Headquarters	Suntechcity
Employees	122
Sector	Health Care
Industries Biotechnology Cosmetics Pharmaceuticals Research & Consulting

Description

L&C BIO Co., Ltd. operates as a research and development company in tissue regeneration medicine. It offers human tissue, medical device, and cosmetics products. The company was founded in 2011 and is headquartered in Seongnam, South Korea.

Key trends

Past 5 years